Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Acorda Therapeutics Inc (ACORQ)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.750 +0.200    +36.36%
25/04 - Closed. Currency in USD ( Disclaimer )
After Hours
0.840
+0.090
+11.987%
15:59:57 - Delayed Data
Type:  Equity
Market:  United States
  • Volume: 37,616
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 0.550 - 0.840
Acorda 0.750 +0.200 +36.36%

OTC:ACORQ Financials

 
A brief overview of the OTC:ACORQ financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Acorda over time.

Acorda Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 27.72 million compared to USD 33.51 million a year ago. Net loss was USD 8.89 million compared to USD 13.85 million a year ago. Basic loss per share from continuing operations was USD 7.16 compared to USD 11.17 a year ago. Diluted loss per share from continuing operations was USD 7.16 compared to USD 11.17 a year ago.For the nine months, revenue was USD 79.65 million compared to USD 87.1 million a year ago. Net loss was USD 35.09 million compared to USD 85.06 million a year ago. Basic loss per share from continuing operations was USD 28.25 compared to USD 97.66 a year ago. Diluted loss per share from continuing operations was USD 28.25 compared to USD 97.66 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

ACORQ Income Statement

Gross margin TTM 82.63%
Operating margin TTM -
Net Profit margin TTM -
Return on Investment TTM -
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 37.98 27.72 29.68 22.26
Gross Profit 31.38 23.12 25.06 17.64
Operating Income 1.48 -7.72 -4.46 -12.57
Net Income -217.76 -8.89 -9.38 -16.82

ACORQ Balance Sheet

Quick Ratio MRQ -
Current Ratio MRQ 0.33
LT Debt to Equity MRQ -
Total Debt to Equity MRQ -
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 108.52 366.34 364.7 374.91
Total Liabilities 266.48 307.39 296.83 297.95
Total Equity -157.96 58.96 67.87 76.96

ACORQ Cash Flow Statement

Cash Flow/Share TTM -
Revenue/Share TTM -
Operating Cash Flow  -1.33%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -3.02 7.61 -11.56 -7.02
Cash From Investing Activities -0.044 -0.22
Cash From Financing Activities
Net Change in Cash -2.97 7.23 -11.4 -6.92
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ACORQ Comments

Write your thoughts about Acorda Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
hussain rahim
hussain rahim Jun 15, 2023 4:09AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
should I buy now? will it go up ?
Luka Tsirekidze
Luka Tsirekidze May 08, 2023 1:42PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
now this stock have big potential in long term 🚀🚀🚀
Giuseppe Giannachi
Giuseppe Giannachi May 08, 2023 1:13PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What will the earnings be like? As usual?
Jack Belforte
Jack Belforte Jan 24, 2023 12:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ACOR may need more news before running to the $1.50 playground.
Jack Belforte
Jack Belforte Jan 12, 2023 5:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Will Acorda become a run away stock this week?
Jack Belforte
Jack Belforte Jan 04, 2023 8:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ACOR time to get in under the dollar levels. May not take much for them to run it higher.
Jack Belforte
Jack Belforte Nov 15, 2022 8:07AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ACOR getting rid of the skeletons in the back closet quietly.
Jack Belforte
Jack Belforte Nov 14, 2022 7:25AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What fun surprises await the bulls with ACOR?
Jack Belforte
Jack Belforte Nov 01, 2022 6:51AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Some had no faith but ACOR us determined to succeed.The powerful accumulation programs have begun. $2+ once we get over the $1.55 traders.
Jack Belforte
Jack Belforte Oct 18, 2022 11:19PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Check the news on ACOR. It's going to propel the stock into the 2s. No dilution, $16.5 million award, no more royalty payments, DEC debt payment will not be done with shares, recent alliance. Great buy opps.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email